Positive data from pivotal phase III study could improve standard of care for Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care, researchers report.